SINOVAC

Sinovac Biotech Ltd. is a biopharmaceutical high-tech enterprise headquartered in Beijing, currently listed on the Nasdaq Global Select Market (NasdaqGS: SVA). Through its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd., the company owns five enterprises: SINOVAC Biotech Ltd., Sinovac (Dalian) Vaccine Technology Co., Ltd., Sinovac Zhongwei Biotechnology Co., Ltd., Sinovac Biotech (Singapore) Ltd., and Sinovac Zhongyi Biopharmaceutical Co., Ltd. It also operates four industrial bases located in Haidian, Changping, Daxing districts of Beijing, and Dalian city in Liaoning province.Sinovac's mission is "to provide vaccines for the elimination of human diseases," focusing on the research, development, production, and sales of human vaccines and related products, as well as providing services for disease prevention and control.The company’s marketed products mainly include: Inactivated COVID-19 Vaccine (CoronaVac®), a Class 1 new preventive biological product – Inactivated Enterovirus 71 Vaccine (Evipar®), China’s first WHO-prequalified Inactivated Hepatitis A Vaccine (Healive®), Trivalent Influenza Virus Split Vaccine (Anflu®) and Quadrivalent Influenza Virus Split Vaccine, Varicella Attenuated Live Vaccine, Mumps Attenuated Live Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine, and Combined Hepatitis A and B Vaccine (Bilive®), among others. Additionally, the company has successively developed the world’s first SARS virus inactivated vaccine (completed Phase I clinical trials), China’s first pandemic influenza (H5N1) vaccine (Panflu®), and the world’s first H1N1 influenza vaccine (Panflu.1®), contributing to disease prevention and control both in China and globally.